Lansoprazole for Injection 30mg (GMP pharmaceutical manufacture)

• Customization: Available
• Application: Internal Medicine
• Usage Mode: Injection
• Model NO.: SLF1018
• Suitable for: Elderly, Children, Adult
• State: Solid
• Shape: Powder
• Type: Inorganic Chemicals
• Pharmaceutical Technology: Chemical Synthesis
• Drug Reg./Approval No.: 300490
• Drug Ad Approval No.: 300490
• Registration Dossiers: Available
• Quality Standard: USP or Bp
• Transport Package: Box
• Specification: 30mg/ml
• Trademark: SHENGLU
• Origin: China
• HS Code: 2804290000
• Production Capacity: 100000000000000/Year

Product Description

lansoprazole for injection 30mg (GMP pharmaceutical manufacture)

Product Description

Molecular Formula

369.36

CAS No.

103577-45-3

Delivery Items

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Lansoprazole is firstly transferred to the acid-producing region of the gastric mucosal parietal cells, and transformed into an activated form through conversion reaction by acid. This reaction product is considered to combine with the SH-groups of (H + , K + )-ATPase which is locally located in the acid-producing region and playing a role of the proton pump, suppressing the enzyme activity to inhibit the acid secretion. It has been reported that blood coagulation and platelet aggregation capacities are severely impaired under acidic conditions, and that fibrin formed as a result of blood coagulation is dissolved by pepsin under acidic conditions. Lansoprazole is considered to increase gastric pH, thereby improving blood coagulation and platelet aggregation capacities and inhibiting peptic activity, resulting in suppression of bleeding. Also, lansoprazole is considered to increase gastric pH by inhibiting acid secretion, thereby promoting repair of injured mucosa, which is inhibited under acidic conditions.

Detailed Photos

Company Profile